EC Number   |
Application |
Reference |
|---|
   3.4.21.89 | analysis |
development of a fluorescence resonance energy transfer-based assay method as a rapid and reliable tool in future research for the identification and validation of potential SPase I inhibitors |
709506 |
| 3.4.21.89 | drug development |
bacterial signal peptidase I (SPase) is a target for development of beta-lactam anti-bacterial inhibitors |
-, 752371 |
| 3.4.21.89 | drug development |
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors |
-, 752959 |
| 3.4.21.89 | drug development |
bacterial type I signal peptidase is a potential target for the development of antibacterial agents |
696677 |
| 3.4.21.89 | drug development |
in the search for antibacterial therapies, the type I signal peptidase serves as a potential target for development of antibacterials with another mode of action. SPase I is also is a feasible target for biofilm-associated infections |
709844 |
| 3.4.21.89 | drug development |
SPase I is a target for development of inhibitors as antibiotics |
707513 |
| 3.4.21.89 | drug development |
SPase I serves as a potentially interesting target for the development of antibacterials with another mode of action |
709506 |
| 3.4.21.89 | drug development |
type I signal peptidase is a potential target for the development of novel antibacterial agents |
696677 |
| 3.4.21.89 | medicine |
developing of medication designed to arrest tissue damage during Pseudomonas infection, opportunistic pathogen causes morbidity and mortality in patients with burns, cystic fibrosis, pneumonia, urinary tract infections, skin infections, cancer, acquired immunodeficiency syndrome, and ocular disease |
-, 651885 |
| 3.4.21.89 | medicine |
inhibition of enzyme by arylomycin A-C16 results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity of cells when combined with an aminoglycoside. Antibiotics tetracycline, erythromycin, and vancomycin each interact additively with arylomycin A-C16, while rifampin and trimethoprim show pronounced antagonism |
731141 |
